Jasper Therapeutics Inc. (JSPR) Stock Price, Quote & News

Company Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chroni...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 549 1400

Website: jaspertx.com

Address:

2200 Bridge Pkwy, Suite 102, Redwood City, United States

Biotech41 May. 22 at 5:39 PM

$JSPR did not hold

0 · Reply

YouVSYou May. 22 at 4:53 PM

$JSPR Nice daily chart

0 · Reply

buttercup1007 May. 22 at 3:23 PM

$JSPR https://www.tipranks.com/news/company-announcements/jasper-therapeutics-announces-board-resignation-and-committee-change?utm_source=webullapp.com&utm_medium=referral

0 · Reply

buttercup1007 May. 22 at 3:17 PM

$JSPR interesting action today

1 · Reply

Biotech41 May. 15 at 2:18 PM

$JSPR red day everywhere, over reaction?

0 · Reply

Mario19860 May. 15 at 2:11 PM

$JSPR disaster

0 · Reply

SuperGreenToday May. 14 at 8:56 PM

$JSPR Share Price: $0.95 Contract Selected: Dec 18, 2026 $0.5 Calls Buy Zone: $0.34 – $0.42 Target Zone: $0.61 – $0.75 Potential Upside: 70% ROI Time to Expiration: 217 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Bullshyte May. 2 at 12:46 PM

$JSPR

1 · Reply

shehww Apr. 30 at 8:50 PM

$JSPR

0 · Reply

Emergency123 Apr. 25 at 9:05 AM

$JSPR 🚀CNBX – Deep Value Biotech Flying Under the Radar 🚀 CNBX is one of those ultra-low market cap biotech plays that could move FAST when attention comes in. 💊 Cancer-Focused Pipeline CNBX is developing multiple cannabinoid-based cancer therapies, including treatments targeting colorectal, breast, prostate, and melanoma cancers. Their lead candidates like Cannabics SR and RCC-33 are aimed at massive global markets. () Got eyes on it?

0 · Reply

Jasper Therapeutics price target lowered to $3 from $4 at RBC Capital

2026-05-15T09:40:09.000Z - 10 days ago

Jasper Therapeutics downgraded to Hold from Buy at TD Cowen

May 14, 2026, 4:05 PM EDT - 10 days ago

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026, 7:00 AM EDT - 11 days ago

Jasper Therapeutics Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 11 days ago

Jasper Therapeutics Earnings release: Q1 2026

2026-04-01T11:59:40.000Z - 7 weeks ago

Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI

2026-03-30T20:37:13.000Z - 7 weeks ago

Jasper Therapeutics reports Q4 EPS (32c), consensus (82c)

Mar 30, 2026, 4:30 PM EDT - 7 weeks ago

Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Mar 30, 2026, 7:00 AM EDT - 2 months ago

Jasper Therapeutics Earnings release: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 2 months ago

Jasper Therapeutics Annual report: Q4 2025

2026-03-23T10:20:58.000Z - 2 months ago

Jasper Therapeutics assumed with a Neutral at UBS

Mar 2, 2026, 3:50 PM EST - 2 months ago

Jasper Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 7:00 AM EST - 2 months ago

Jasper Therapeutics Slides: Corporate presentation

Feb 24, 2026, 4:30 PM EST - 3 months ago

Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

2026-01-13T20:20:15.000Z - 4 months ago

Jasper Therapeutics initiated with a Buy at Rodman & Renshaw

Jan 8, 2026, 8:00 AM EST - 4 months ago

Jasper Therapeutics Transcript: Study Result

Jan 8, 2026, 8:00 AM EST - 4 months ago

Jasper Therapeutics Press release: Study Result

Jan 8, 2026, 8:00 AM EST - 4 months ago

Jasper Therapeutics Slides: Study Result

2026-01-08T12:15:17.000Z - 4 months ago

Jasper Therapeutics reports updated data from briquilimab studies

Jan 8, 2026, 7:00 AM EST - 4 months ago

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

2026-01-07T21:35:34.000Z - 4 months ago

Jasper Therapeutics says Jeet Mahal to succeed Ronald Martell as CEO

Jan 7, 2026, 4:30 PM EST - 4 months ago

Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth

2025-12-04T16:57:00.000Z - 6 months ago

3 Penny Stocks to Watch Now, 12/4/25

Dec 3, 2025, 3:00 PM EST - 6 months ago

Jasper Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 8:00 AM EST - 6 months ago

Jasper Therapeutics Transcript: Study Result

Dec 2, 2025, 8:00 AM EST - 6 months ago

Jasper Therapeutics Press release: Study Result

Dec 2, 2025, 8:00 AM EST - 6 months ago

Jasper Therapeutics Slides: Study Result

2025-12-02T12:10:33.000Z - 6 months ago

Jasper Therapeutics reports data from ETESIAN Phase 1b study

Dec 2, 2025, 7:00 AM EST - 6 months ago

Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

Dec 1, 2025, 4:30 PM EST - 6 months ago

Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

Nov 12, 2025, 3:30 PM EST - 6 months ago

Jasper Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 11, 2025, 4:00 PM EST - 6 months ago

Jasper Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 7:00 AM EST - 6 months ago

Jasper Therapeutics Slides: Investor Presentation

2025-11-10T13:05:12.000Z - 6 months ago

Jasper Therapeutics reports Q3 EPS ($1.13), consensus ($1.29)

Nov 10, 2025, 8:00 AM EST - 6 months ago

Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 10, 2025, 8:00 AM EST - 6 months ago

Jasper Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 8:00 AM EST - 6 months ago

Jasper Therapeutics Earnings release: Q3 2025

Nov 9, 2025, 6:00 PM EST - 7 months ago

Jasper Therapeutics Slides: Corporate Presentation

Nov 4, 2025, 8:00 AM EST - 7 months ago

Jasper Therapeutics to Present at Upcoming Investor Conferences

Sep 22, 2025, 1:05 PM EDT - 8 months ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. (JSPR)

2025-09-22T10:55:06.000Z - 8 months ago

Jasper Therapeutics price target lowered to $6 from $12 at Citizens JMP

2025-09-19T10:00:28.000Z - 8 months ago

Jasper Therapeutics 11.67M share Spot Secondary priced at $2.43

Sep 19, 2025, 12:07 AM EDT - 8 months ago

Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

2025-09-18T20:15:24.000Z - 8 months ago

Jasper Therapeutics announces common stock offering, no amount given

Sep 18, 2025, 4:08 PM EDT - 8 months ago

Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Sep 3, 2025, 1:00 PM EDT - 9 months ago

Jasper Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 2, 2025, 6:00 PM EDT - 9 months ago

Jasper Therapeutics Slides: Corporate Presentation

2025-08-15T11:35:55.000Z - 10 months ago

Jasper Therapeutics price target lowered to $25 from $29 at UBS

2025-08-13T20:35:13.000Z - 10 months ago

Jasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33)

Aug 13, 2025, 4:05 PM EDT - 10 months ago

Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 7:00 AM EDT - 10 months ago

Jasper Therapeutics Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 10 months ago

Jasper Therapeutics Quarterly report: Q2 2025

2025-07-09T12:15:18.000Z - 11 months ago

Jasper Therapeutics to reduce workforce by 50%, focus on Chronic Urticaria

Jul 9, 2025, 8:00 AM EDT - 11 months ago

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

2025-07-08T10:25:33.000Z - 11 months ago

RBC downgrades Jasper Therapeutics on questions about briquilimab

CLDX

2025-07-08T09:45:23.000Z - 11 months ago

Jasper Therapeutics price target lowered to $12 from $70 at Citizens JMP

2025-07-08T09:10:18.000Z - 11 months ago

Jasper Therapeutics downgraded to Sector Perform from Outperform at RBC Capital

Jul 7, 2025, 8:30 AM EDT - 11 months ago

Jasper Therapeutics Transcript: Study Update

Jul 7, 2025, 8:30 AM EDT - 11 months ago

Jasper Therapeutics Press release: Study Update

Jul 7, 2025, 8:30 AM EDT - 11 months ago

Jasper Therapeutics Slides: Study Update

Jul 7, 2025, 7:30 AM EDT - 11 months ago

Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria

Jun 24, 2025, 8:30 AM EDT - 11 months ago

Jasper Therapeutics Slides: Investor Presentation

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Transcript: Status Update

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Press release: Status Update

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Slides: Status Update

Jun 14, 2025, 10:00 AM EDT - 1 year ago

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Jun 5, 2025, 11:40 AM EDT - 1 year ago

Jasper Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

May 21, 2025, 11:00 AM EDT - 1 year ago

Jasper Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 19, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Proxy statement: Proxy Filing

May 19, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Proxy statement: Proxy Filing

May 12, 2025, 4:05 PM EDT - 1 year ago

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 9:30 AM EDT - 1 year ago

Jasper Therapeutics Earnings release: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

Jasper Therapeutics Quarterly report: Q1 2025

Mar 27, 2025, 12:30 PM EDT - 1 year ago

Jasper Therapeutics Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Registration statement: Registration Filing

Mar 3, 2025, 1:20 PM EST - 1 year ago

Jasper Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 1, 2025, 12:45 PM EST - 1 year ago

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 28, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Feb 27, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Feb 27, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Annual report: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Earnings release: Q4 2024

Feb 25, 2025, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Present at Upcoming March Investor Conferences

Feb 10, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 4, 2025, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Jan 8, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Transcript: Study Update

Jan 8, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Press release: Study Update

Jan 8, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Slides: Study Update

Jan 8, 2025, 7:00 AM EST - 1 year ago

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jan 6, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Dec 3, 2024, 3:25 PM EST - 1 year ago

Jasper Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 2, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Nov 18, 2024, 9:45 AM EST - 1 year ago

Jasper Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 13, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Participate at Upcoming Investor Conferences

Nov 7, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Quarterly report: Q3 2024

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 14, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Transcript: Study Result

Oct 14, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Press release: Study Result

Oct 14, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Slides: Study Result

Oct 14, 2024, 7:00 AM EDT - 1 year ago

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Sep 20, 2024, 12:00 PM EDT - 1 year ago

Jasper Therapeutics Transcript: TD Cowen Chronic Urticaria Summit

Sep 17, 2024, 2:30 PM EDT - 1 year ago

Jasper Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2024, 3:00 PM EDT - 1 year ago

Jasper Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 10, 2024, 7:30 AM EDT - 1 year ago

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma

Sep 10, 2024, 6:00 AM EDT - 1 year ago

Jasper Therapeutics Slides: Corporate Presentation

Sep 4, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences

Aug 13, 2024, 9:30 AM EDT - 1 year ago

Jasper Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 9:30 AM EDT - 1 year ago

Jasper Therapeutics Earnings release: Q2 2024

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

Biotech41 May. 22 at 5:39 PM

$JSPR did not hold

0 · Reply

YouVSYou May. 22 at 4:53 PM

$JSPR Nice daily chart

0 · Reply

buttercup1007 May. 22 at 3:23 PM

$JSPR https://www.tipranks.com/news/company-announcements/jasper-therapeutics-announces-board-resignation-and-committee-change?utm_source=webullapp.com&utm_medium=referral

0 · Reply

buttercup1007 May. 22 at 3:17 PM

$JSPR interesting action today

1 · Reply

Biotech41 May. 15 at 2:18 PM

$JSPR red day everywhere, over reaction?

0 · Reply

Mario19860 May. 15 at 2:11 PM

$JSPR disaster

0 · Reply

SuperGreenToday May. 14 at 8:56 PM

0 · Reply

Bullshyte May. 2 at 12:46 PM

$JSPR

1 · Reply

shehww Apr. 30 at 8:50 PM

$JSPR

0 · Reply

Emergency123 Apr. 25 at 9:05 AM

0 · Reply

KOWALSK1 Apr. 20 at 6:53 PM

$JSPR 62%

0 · Reply

Bullshyte Apr. 20 at 6:39 PM

$JSPR https://www.msn.com/en-us/money/markets/jasper-shares-surge-following-encouraging-early-asthma-trial-data/ar-AA1Rz7Hy?ocid=BingNewsVerp

1 · Reply

Bullshyte Apr. 18 at 6:21 AM

$JSPR Extremely

0 · Reply

KOWALSK1 Apr. 17 at 9:39 PM

$JSPR 46% 💥 💥 💥

0 · Reply

Mario19860 Apr. 17 at 5:28 PM

$JSPR what this mean?

0 · Reply

shehww Apr. 16 at 3:32 PM

$JSPR next stop 1.45$ 😊

0 · Reply

shehww Apr. 16 at 1:15 PM

$JSPR ...🔥🔥🔥

0 · Reply

Mario19860 Apr. 16 at 12:19 PM

$JSPR whats happening?

0 · Reply

KOWALSK1 Apr. 16 at 10:09 AM

$JSPR

0 · Reply

KOWALSK1 Apr. 16 at 10:03 AM

$JSPR

0 · Reply

Bullshyte Apr. 15 at 6:30 PM

$JSPR

0 · Reply

Chrissytina Apr. 15 at 5:56 PM

$JSPR Whatever you do…just close above $1 everyday!

0 · Reply

Market Cap	25.28M
Revenue (ttm)	0.00
Net Income (ttm)	-75.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	680,300
Avg Vol	419,824
Day's Range	N/A - N/A
Shares Out	28.00M
Stochastic %K	54%
Beta	3.07
Analysts	Sell
Price Target	$7.50